[{"orgOrder":0,"company":"Holoclara","sponsor":"BOLD Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"Worm-derived Drug","moa":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Holoclara","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"","sponsorNew":"Holoclara \/ BOLD Capital Partners","highestDevelopmentStatusID":"3","companyTruncated":"Holoclara \/ BOLD Capital Partners"}]

Find Clinical Drug Pipeline Developments & Deals by Holoclara

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The capital will be used to support clinical development of first-in-class, worm-derived medicines for allergies and autoimmune disorders and advancement of discovery engine.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 27, 2024

                          Lead Product(s) : Worm-derived Drug

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery Platform

                          Sponsor : BOLD Capital Partners

                          Deal Size : $16.0 million

                          Deal Type : Series A Financing

                          blank